Two Sigma Advisers
EDIT icon

Two Sigma Advisers’s Editas Medicine EDIT Stock Holding History

Two Sigma Advisers’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,224,100
Closed -$2.51M – 656
2025
Q4 		$2.51M Buy
1,224,100
+19,100
+2% +$55.1K ﹤0.01% 1088
2025
Q3 		$4.18M Buy
1,205,000
+264,400
+28% +$738K 0.01% 808
2025
Q2 		$2.07M Sell
940,600
-274,400
-23% -$449K ﹤0.01% 1100
2025
Q1 		$1.41M Sell
1,215,000
-442,000
-27% -$650K ﹤0.01% 1297
2024
Q4 		$2.1M Buy
1,657,000
+528,000
+47% +$1.35M ﹤0.01% 1100
2024
Q3 		$3.85M Buy
1,129,000
+272,500
+32% +$1.19M 0.01% 797
2024
Q2 		$4M Sell
856,500
-377,800
-31% -$2.13M 0.01% 866
2024
Q1 		$9.16M Buy
1,234,300
+92,800
+8% +$771K 0.02% 563
2023
Q4 		$11.6M Buy
1,141,500
+66,500
+6% +$584K 0.03% 472
2023
Q3 		$8.38M Buy
1,075,000
+284,600
+36% +$2.44M 0.02% 524
2023
Q2 		$6.5M Sell
790,400
-110,600
-12% -$964K 0.02% 656
2023
Q1 		$6.53M Sell
901,000
-194,500
-18% -$1.73M 0.02% 701
2022
Q4 		$9.72M Buy
1,095,500
+19,000
+2% +$209K 0.03% 522
2022
Q3 		$13.2M Buy
1,076,500
+100,000
+10% +$1.56M 0.04% 426
2022
Q2 		$11.6M Buy
976,500
+93,000
+11% +$1.25M 0.03% 470
2022
Q1 		$16.8M Buy
883,500
+124,100
+16% +$2.31M 0.04% 362
2021
Q4 		$20.2M Buy
759,400
+346,500
+84% +$11.9M 0.05% 306
2021
Q3 		$17M Sell
412,900
-253,900
-38% -$13.9M 0.04% 356
2021
Q2 		$37.8M Buy
666,800
+71,300
+12% +$2.63M 0.1% 213
2021
Q1 		$25M Buy
595,500
+186,900
+46% +$10.6M 0.07% 304
2020
Q4 		$28.6M Sell
408,600
-224,600
-35% -$9.23M 0.08% 262
2020
Q3 		$17.8M Buy
633,200
+27,000
+4% +$879K 0.05% 352
2020
Q2 		$17.9M Sell
606,200
-900
-0.1% -$23.5K 0.05% 354
2020
Q1 		$12M Buy
607,100
+189,600
+45% +$4.78M 0.05% 423
2019
Q4 		$12.4M Buy
417,500
+114,500
+38% +$2.86M 0.03% 526
2019
Q3 		$6.89M Buy
303,000
+129,200
+74% +$3.2M 0.02% 659
2019
Q2 		$4.3M Buy
173,800
+61,900
+55% +$1.48M 0.01% 891
2019
Q1 		$2.74M Buy
111,900
+5,600
+5% +$127K 0.01% 1085
2018
Q4 		$2.42M Buy
106,300
+19,100
+22% +$520K 0.01% 1092
2018
Q3 		$2.77M Buy
87,200
+1,600
+2% +$51.7K 0.01% 1076
2018
Q2 		$3.07M Buy
85,600
+35,100
+70% +$1.24M 0.01% 1090
2018
Q1 		$1.67M Buy
50,500
+24,000
+91% +$855K ﹤0.01% 1329
2017
Q4 		$814K Buy
+26,500
New +$667K ﹤0.01% 1594

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers's EDIT Position: Q1 2026 in Review

Two Sigma Advisers sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 1,224,100 shares — an estimated $2.51M sold.

Two Sigma Advisers first reported a position in EDIT in Q4 2017 and held it in 33 quarters. The position peaked at $37.8M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Two Sigma Advisers reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,224,100 Editas Medicine shares in Q1 2026, an estimated $2.51M.
  • Two Sigma Advisers first reported a position in Editas Medicine in Q4 2017 and held it in 33 quarters.
  • Two Sigma Advisers's Editas Medicine position peaked at $37.8M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.